Latest News

Image credit: klickit24 | stock.adobe.com
Potential First in Class Treatment for Cirrhosis Shows Positive Results in Phase II Trial

March 28th 2024

LPCN 1148 is an oral treatment that has shown promise preventing recurrence of overt hepatic encephalopathy and treating sarcopenia.

Veeva Heroes
CSL Behring and Takeda Discuss Advancing Clinical Development and the Future of Trials

March 28th 2024

What is Elysium Therapeutics' O2P?
What is Elysium Therapeutics' O2P?

March 28th 2024

© Sergey Nivens - © Sergey Nivens - stock.adobe.com
How Often are Retracted microRNA Biomarker Articles Cited in Future Research?

March 27th 2024

Image credit: pressmaster | stock.adobe.com
FDA Fast Tracks Johnson & Johnson’s Nipocalimab for Fetal Neonatal Alloimmune Thrombocytopenia

March 27th 2024

Conference Coverage

View All
SCOPE 2024: YPrime CEO, Jim Corrigan Speaks About the Company and Addressing Uncertainty in Clinical Trials
SCOPE 2024: YPrime CEO, Jim Corrigan Speaks About the Company and Addressing Uncertainty in Clinical Trials

February 19th 2024

SCOPE 2024: Alex Deyle of Flatiron Health Discusses RWD in Clinical Trials
SCOPE 2024: Alex Deyle of Flatiron Health Discusses RWD in Clinical Trials

February 14th 2024

SCOPE 2024: Steve Young of CluePoints Discusses RBQM and Key Risk Indicators
SCOPE 2024: Steve Young of CluePoints Discusses RBQM and Key Risk Indicators

February 13th 2024

SCOPE 2024: Todd Everhart of Signant Health Discusses DCTs and Site Burden
SCOPE 2024: Todd Everhart of Signant Health Discusses DCTs and Site Burden

February 13th 2024

Latest Videos
Podcasts
© Alex from the Rock - © Alex from the Rock - stock.adobe.com
Rinol Alaj, Jaclyn Patterson, Applied Clincial Trials Podcast

All News

© 2024 MJH Life Sciences

All rights reserved.